Both Tirzepatide and Semaglutide GLP-1 belong to a new and increasingly popular class of drugs that work by mimicking hormones that regulate appetite and metabolism, offering a more effective and sustainable approach to weight management compared to older medications
Unlike semaglutide, tirzepatide is a dual receptor agonist targeting both GLP1R and GIPR
Future therapeutic approaches may involve: Microbiome-targeted therapies Gut-derived peptide treatments Personalized nutrition based on microbial composition These emerging strategies reflect a broader shift in metabolic medicine toward addressing root causes rather than simply managing symptoms
Lire aussiMolcule "miracle" GLP-1 : des effets secondaires surveiller Larrt du traitement "peut tre ncessaire notamment en cas dabsence defficacit" Selon la HAS, larrt du traitement "peut tre ncessaire notamment en cas dabsence defficacit" , qu'elle dfinit notamment comme une perte de poids 6 mois de moins de 5%, ou une absence de son maintien, ou encore la poursuite de la prise de poids
(Source 3) Benefits might be even more significant and faster with liposomal glutathione, which we'll discuss next